drugset / Trial / NCT03333603

Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients

NCT03333603

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetic and safety for the esomeprazole use for schizophrenia

Timeline

Start
2016-05-23
Primary completion
2017-01-23
Completion
2017-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 80 mg Oral

Indications